Achilles Therapeutics plc (NASDAQ:ACHL – Get Rating) – Analysts at Oppenheimer reduced their Q1 2023 earnings per share estimates for Achilles Therapeutics in a report released on Tuesday, March 7th. Oppenheimer analyst M. Breidenbach now anticipates that the company will post earnings of ($0.49) per share for the quarter, down from their prior estimate of ($0.38). Oppenheimer has a "Market Perform" rating on the stock. The consensus estimate for Achilles Therapeutics' current full-year earnings is ($1.66) per share. Oppenheimer also issued estimates for Achilles Therapeutics' Q2 2023 earnings at ($0.49) EPS, Q3 2023 earnings at ($0.49) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($1.96) EPS, FY2024 earnings at ($1.55) EPS, FY2025 earnings at ($1.72) EPS and FY2026 earnings at ($1.85) EPS.
Get Achilles Therapeutics alerts:ACHL has been the subject of a number of other reports. Piper Sandler cut their target price on Achilles Therapeutics from $10.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, December 6th. Chardan Capital lowered their target price on Achilles Therapeutics from $17.00 to $12.00 in a report on Wednesday.
Achilles Therapeutics Stock Down 4.5 %
Shares of NASDAQ ACHL opened at $0.95 on Friday. The stock has a market cap of $37.19 million, a PE ratio of -0.52 and a beta of 0.98. The company has a quick ratio of 10.43, a current ratio of 10.93 and a debt-to-equity ratio of 0.02. Achilles Therapeutics has a 52-week low of $0.75 and a 52-week high of $3.45. The business has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.73.
Institutional Trading of Achilles Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC boosted its stake in Achilles Therapeutics by 498.2% in the fourth quarter. Renaissance Technologies LLC now owns 484,733 shares of the company's stock valued at $436,000 after acquiring an additional 403,700 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Achilles Therapeutics by 18.6% in the third quarter. Point72 Asset Management L.P. now owns 2,107,595 shares of the company's stock valued at $4,763,000 after buying an additional 330,851 shares in the last quarter. Kettle Hill Capital Management LLC bought a new position in shares of Achilles Therapeutics in the second quarter valued at $612,000. Millennium Management LLC bought a new position in shares of Achilles Therapeutics in the fourth quarter valued at $74,000. Finally, BlackRock Inc. grew its position in Achilles Therapeutics by 25.5% during the 1st quarter. BlackRock Inc. now owns 266,657 shares of the company's stock worth $784,000 after purchasing an additional 54,225 shares in the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
About Achilles Therapeutics
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Achilles Therapeutics (ACHL)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.